Sean Pitroda to Biomarkers, Tumor
This is a "connection" page, showing publications Sean Pitroda has written about Biomarkers, Tumor.
Connection Strength
0.971
-
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
Score: 0.459
-
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
Score: 0.107
-
Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease. Cancer J. 2020 Mar/Apr; 26(2):96-99.
Score: 0.103
-
JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers. Mol Cancer Ther. 2018 04; 17(4):732-739.
Score: 0.089
-
Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers. Sci Rep. 2016 10 24; 6:35854.
Score: 0.081
-
Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
Score: 0.079
-
MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics. 2010 May 06; 3:16.
Score: 0.052